Financial Performance - The company's revenue for Q1 2022 was ¥129,549,459.57, a decrease of 10.22% compared to ¥144,296,323.22 in the same period last year[4] - Net profit attributable to shareholders was ¥28,439,239.02, down 5.57% from ¥30,115,863.50 year-on-year[4] - Basic and diluted earnings per share decreased by 28.13% to ¥0.23 from ¥0.32 in the same period last year[4] - Total operating revenue for the current period was CNY 129,549,459.57, a decrease of 10.2% from CNY 144,296,323.22 in the previous period[32] - Net profit for the current period was CNY 28,439,239.02, a decline of 5.6% compared to CNY 30,115,863.50 in the previous period[35] - The total comprehensive income for the current period was CNY 28,439,239.02, compared to CNY 30,603,544.42 in the previous period, indicating a decline of about 7.1%[35] Cash Flow - The net cash flow from operating activities was -¥3,072,039.33, a significant decline of 113.50% compared to ¥22,752,897.85 in the previous year[4] - Cash inflow from operating activities totaled 87,162,014.29 yuan, down from 103,973,877.71 yuan in the previous period, representing a decrease of approximately 16.2%[38] - Cash outflow from operating activities increased to 90,234,053.62 yuan from 81,220,979.86 yuan, marking an increase of about 11.8%[38] - Cash inflow from investment activities amounted to 221,889,021.11 yuan, with a net cash flow of 37,691,425.55 yuan, compared to -24,544,104.59 yuan in the previous period[41] - Cash inflow from financing activities was 10,000,000.00 yuan, down from 28,600,000.00 yuan in the previous period, a decrease of approximately 65%[41] - The net cash flow from financing activities was 3,379,893.06 yuan, recovering from -11,076,570.51 yuan in the previous period[41] - The ending balance of cash and cash equivalents increased to 272,345,621.68 yuan from 54,420,638.37 yuan, reflecting a significant increase[41] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,400,961,990.16, reflecting a slight increase of 0.52% from ¥1,393,711,531.79 at the end of the previous year[4] - The total liabilities decreased to CNY 275,163,113.83 from CNY 296,351,894.49, reflecting a reduction of approximately 7.1%[28] - The company's cash and cash equivalents increased to CNY 313.12 million from CNY 284.20 million at the beginning of the year, reflecting a growth of approximately 10.2%[21] - Inventory levels rose to CNY 200.60 million, up from CNY 167.08 million, indicating an increase of about 19.99%[24] - The company's short-term borrowings increased to CNY 69.50 million from CNY 64.50 million, representing an increase of approximately 7.77%[24] - Accounts payable decreased to CNY 82.14 million from CNY 95.32 million, a decline of about 13.76%[24] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 35,115, with the largest shareholder holding 27.34% of the shares[12] - The company reported a total of 96,022,168 shares with restrictions on sale as of the reporting period[19] - The number of shareholders holding restricted shares at the end of the reporting period was 34,446,500, with a planned release date of October 26, 2024[16] Expenses - Management expenses rose by 44.72% to ¥18,200,219.61, primarily due to increases in employee compensation and depreciation[8] - Other income increased by 76.77% to ¥2,820,778.33, mainly due to higher government subsidies received[8] - The company reported a significant increase of 215.41% in taxes payable, amounting to ¥8,535,535.03, attributed to the accrual of income tax at the end of the period[8] - Research and development expenses increased to CNY 5,490,392.24, up 19% from CNY 4,613,873.30 in the previous period[32] - The company reported a decrease in sales expenses to CNY 1,965,133.65 from CNY 2,446,560.45, a reduction of approximately 19.6%[32]
拓新药业(301089) - 2022 Q1 - 季度财报